文献速递细菌感染、耐药与抗菌药物

多粘菌素治疗多重耐药病原体的临床进展

Advances in the clinical treatment of multidrug-resistant pathogens using polymyxins.
PubMed 文献 · J Antimicrob Chemother · 2024-01-01

本综述分析多粘菌素治疗碳青霉烯类耐药革兰阴性菌(CR-GNB)感染的临床进展,涵盖静脉滴注、雾化或干粉吸入及软膏应用等给药方式,评估细菌清除率、治愈率和死亡率。临床试验证实,在制剂和给药方式适当时,多粘菌素可有效治疗CR-GNB感染,肾毒性可接受。未来制剂开发旨在提高疗效、降低毒性并防止耐药菌株出现。

要点

  • 多粘菌素因CR-GNB流行而重新用于危重感染治疗。
  • 给药方式包括静脉滴注、雾化或干粉吸入及软膏应用。
  • 制剂和给药适当时多粘菌素有效且肾毒性可接受。

核心结论

  • 临床试验和研究表明,当制剂和给药方式适当时,多粘菌素可有效治疗CR-GNB感染,肾毒性水平可接受。
  • 未来多粘菌素制剂的开发将旨在提高临床疗效,同时降低毒性和副作用,并防止多粘菌素耐药菌株的出现。
  • 通过开发新型多粘菌素递送系统(实现智能控释或定制化患者给药),可实现疗效增强和潜在副作用最小化。

研究设计与样本

  • 本综述分析关于多粘菌素特性及多种临床给药方式(包括静脉滴注、雾化或干粉吸入及软膏应用)的文献。
  • 综述评估了细菌清除率、治愈率和死亡率方面的治疗疗效。

主要发现

  • 由于CR-GNB流行率增加,多粘菌素已被重新引入用于治疗危重感染。
  • 临床试验和研究证实,当制剂和给药适当时,多粘菌素可有效治疗CR-GNB感染,肾毒性水平可接受。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Polymyxins are a vital class of antibiotics used to combat multidrug-resistant Gram-negative bacteria. However, their use is limited due to potential nephrotoxicity and the availability of alternative antibiotics. This review aims to examine the properties of polymyxins and the clinical advances in their use for treating infections caused by carbapenem-resistant Gram-negative bacteria (CR-GNB). METHODS: This review analyses literature on polymyxin properties and various clinical approaches, including intravenous drip infusion, nebulized or dry powder inhalation, and ointment application. Treatment efficacy in terms of bacterial eradication, cure rate and mortality rate are reviewed and evaluated. RESULTS: Polymyxins have been reintroduced to treat critical infections due to the increasing prevalence of CR-GNB. Clinical trials and studies have confirmed that polymyxins can effectively treat CR-GNB infections when the formulation and administration are appropriate, with acceptable levels of nephrotoxicity. CONCLUSIONS: In the future, the development of polymyxin formulations will aim to improve their clinical effectiveness while reducing toxicity and side effects and preventing the emergence of polymyxin-resistant strains. Enhanced efficacy and minimized potential side effects can be achieved by developing new polymyxin-delivery systems that provide a smart and controlled release or customized patient administration.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Huang Y, Liao M, Hu X, et al. Advances in the clinical treatment of multidrug-resistant pathogens using polymyxins. J Antimicrob Chemother. 2024. PMID: 39351975. doi:10.1093/jac/dkae344

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。